# Arrowhead Pharmaceuticals (ARWR) — News

ARWR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/arwr/news

## Recent headlines

- [Arrowhead's Aro-Mapt cuts tau up to 73% in phase 1/2A](https://www.ainvest.com/news/arrowhead-aro-mapt-cuts-tau-73-phase-1-2a-2610) — AInvest Wire, Oct 14, 2026
  Arrowhead Pharmaceuticals has reported preliminary data from its phase 1/2a clinical trial for ARO-MAPT, an RNA interference therapy targeting the MAPT gene responsible for producing tau protein. The trial demonstrated reduction in tau levels of up to 73% in participants, marking a significant…
- [Arrowhead's trim platform achieves clinical validation](https://www.ainvest.com/news/arrowhead-trim-platform-achieves-clinical-validation-2610) — AInvest Wire, Oct 14, 2026
  Arrowhead Pharmaceuticals has announced that its TRIM (Targeted RNA Interference Mediated) platform has achieved clinical validation, marking a significant milestone in the company’s research and development efforts. The platform, which enables the delivery of RNA interference therapeutics to…
- [Arrowhead Pharmaceuticals - Aro-mapt generally well tolerated, most adverse events mild, no serious teaes reported](https://www.ainvest.com/news/arrowhead-pharmaceuticals-aro-mapt-generally-tolerated-adverse-events-mild-teaes-reported-2610) — AInvest Wire, Oct 14, 2026
- [Arrowhead Pharmaceuticals - To complete dosing in healthy volunteers, data updates expected in 2027](https://www.ainvest.com/news/arrowhead-pharmaceuticals-complete-dosing-healthy-volunteers-data-updates-expected-2027-2610) — AInvest Wire, Oct 14, 2026
- [Arrowhead Pharmaceuticals announces aro-mapt interim phase 1/2A clinical data demonstrating deep and durable tau reductions in healthy volunteers](https://www.ainvest.com/news/arrowhead-pharmaceuticals-announces-aro-mapt-interim-phase-1-2a-clinical-data-demonstrating-deep-durable-tau-reductions-healthy-volunteers-2610) — AInvest Wire, Oct 14, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).